362 related articles for article (PubMed ID: 31896937)
1. A primer on the genetics of medullary thyroid cancer.
Larouche V; Akirov A; Thomas CM; Krzyzanowska MK; Ezzat S
Curr Oncol; 2019 Dec; 26(6):389-394. PubMed ID: 31896937
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
4. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
5. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
6. RET codon 609 mutations: a contribution for better clinical managing.
Mian C; Sartorato P; Barollo S; Zane M; Opocher G
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703
[TBL] [Abstract][Full Text] [Related]
7. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
8. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.
Kouvaraki MA; Shapiro SE; Perrier ND; Cote GJ; Gagel RF; Hoff AO; Sherman SI; Lee JE; Evans DB
Thyroid; 2005 Jun; 15(6):531-44. PubMed ID: 16029119
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
Eng C; Mulligan LM
Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
[TBL] [Abstract][Full Text] [Related]
10. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
11. Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R.
Zwolak A; Rudzki G; Świrska J; Dudzińska M; Daniluk J; Tarach J
Endokrynol Pol; 2015; 66(5):462-8. PubMed ID: 26457501
[TBL] [Abstract][Full Text] [Related]
12. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
[TBL] [Abstract][Full Text] [Related]
13. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Newly Identified and Rare Synonymous Genetic Variants in the RET Gene in Patients with Medullary Thyroid Carcinoma in Polish Population.
Sromek M; Czetwertyńska M; Tarasińska M; Janiec-Jankowska A; Zub R; Ćwikła M; Nowakowska D; Chechlińska M
Endocr Pathol; 2017 Sep; 28(3):198-206. PubMed ID: 28647780
[TBL] [Abstract][Full Text] [Related]
15. RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.
Quedas EP; Longuini VC; Sekiya T; Coutinho FL; Toledo SP; Tannuri U; Toledo RA
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):57-61. PubMed ID: 22584707
[TBL] [Abstract][Full Text] [Related]
16. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
18. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Krampitz GW; Norton JA
Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
[TBL] [Abstract][Full Text] [Related]
19. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
20. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.
Dvorakova S; Vaclavikova E; Ryska A; Cap J; Vlcek P; Duskova J; Kodetova D; Holub V; Novak Z; Bendlova B
Exp Clin Endocrinol Diabetes; 2006 Apr; 114(4):192-6. PubMed ID: 16705552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
